P654: IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH COMPLEX KARYOTYPE AND CHRONIC LYMPHOCYTIC LEUKEMIA

Ítems similars

• Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
  per: Isacco Ferrarini, et al.
  Publicat: (2022-04-01)
• Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
  per: Natalia Timofeeva, et al.
  Publicat: (2023-05-01)
• Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors
  per: E. A. Dmitrieva, et al.
  Publicat: (2019-10-01)
• Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review
  per: Adam Yuh Lin, et al.
  Publicat: (2020-11-01)
• Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
  per: Elżbieta Iskierka-Jażdżewska, et al.
  Publicat: (2025-01-01)